EMBC
Embecta Corp.
EMBC has the edge over NVO overall, supported by stronger valuation and stronger fundamentals.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
EMBC Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Healthy | |
| Strong | |
| Weak |
EMBC's profitability and cash flow are currently healthy, but its revenue and balance sheet are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
EMBC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 3.6x | $6.43 | — |
| Cheap | 4.2x | $6.18 | -3.9% |
| Current | 4.4x | $6.43 | — |
| Fair | 11x | $16.52 | +157% |
| Expensive | 15x | $22.04 | +243% |
Historical ranges are pointers, not guarantees.
EMBC's PE is in its cheap range at 4.4x. If earnings grow as analysts expect, today's price would be 3.6x next year's earnings.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over EMBC in the historical PE scenario, which offers more potential upside but is not a forecast.
EMBC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Stable | |
| Limited | |
| Low |
Analysts expect EMBC's earnings to grow, with its revenue and profitability holding steady. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
EMBC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.81 | +23% |
| Q2 2026 | $1.47 | +3.5% |
| Q1 2026 | $1.89 | +112% |
| Q4 2025 | $2.36 | +138% |
| Q3 2025 | $1.62 | +21% |
| Q2 2025 | $1.42 | +17% |
| Q1 2025 | $0.89 | -27% |
| Q4 2024 | $0.99 | +3.1% |
| Q3 2024 | $1.34 | +9.8% |
EMBC's earnings per share have fallen from their peak: $1.47 over the past year, against $7.28 in late 2021.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over EMBC on earnings, with more consistent year-over-year improvement.
EMBC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $271.7M | -8.1% |
| Q1 2026 | $221.8M | -14% |
| Q4 2025 | $261.2M | -0.3% |
| Q3 2025 | $264M | -7.7% |
| Q2 2025 | $295.5M | +8.4% |
| Q1 2025 | $259M | -9.8% |
| Q4 2024 | $261.9M | -5.6% |
| Q3 2024 | $286.1M | +1.5% |
EMBC's revenue is shrinking: $272M last quarter, down 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 18% | -14 points |
| Q1 2026 | 16% | -8.5 points |
| Q4 2025 | 32% | +21 points |
| Q3 2025 | 21% | +12 points |
| Q2 2025 | 32% | +11 points |
| Q1 2025 | 24% | +11 points |
| Q4 2024 | 11% | -5.4 points |
| Q3 2024 | 9.2% | 0 points |
EMBC's operating margin was 18% last quarter, down 14 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over EMBC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over EMBC on profitability, with a higher operating margin.
EMBC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $40.7M | -50% |
| Q1 2026 | $30.6M | -3.5% |
| Q4 2025 | $16.6M | +$23.4M |
| Q3 2025 | $76.7M | +188% |
| Q2 2025 | $80.8M | +$92.6M |
| Q1 2025 | $31.7M | +52% |
| Q4 2024 | -$6.8M | +$9M |
| Q3 2024 | $26.6M | +30% |
EMBC has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
EMBC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.3% | -787K shares |
| 1 year | 0% | +17K shares |
| 3 years | +1.6% | +930K shares |
| 5 years | +2.7% | +1.5M shares |
EMBC has 59M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over EMBC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
EMBC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 4.6x | High |
| Q1 2026 | 3.7x | Elevated |
| Q4 2025 | 3.4x | Elevated |
| Q3 2025 | 4.2x | High |
| Q2 2025 | 5.0x | High |
| Q1 2025 | 6.2x | High |
| Q4 2024 | 7.1x | High |
| Q3 2024 | 6.4x | High |
EMBC's net debt is about 4.6 years of its operating earnings (EBITDA), down from 5.0 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over EMBC on leverage, with a lower net debt burden relative to earnings.
EMBC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.7 | Neutral |
| Stochastic | 81.2 | Overbought |
EMBC's weekly RSI is 55 (neutral) and its Stochastic is 81 (overbought).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
EMBC PE vs Healthcare Sector
| Metric | EMBC | Sector median | Relative |
|---|---|---|---|
| PE | 4.4x | 26x | 83% below |
| PE % | 19 | 43 | 24 pts below |
EMBC has the edge over NVO on valuation relative to its sector.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
EMBC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.14 | 4.7% above |
| 20 week MA | $5.08 | 27% above |
| 50 week MA | $7.14 | 9.9% below |
| 100 week MA | $10.4 | 38% below |
| 200 week MA | $14.4 | 55% below |
EMBC has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
EMBC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $43.0 | $27.5 | -36% |
| 2023 | $27.5 | $18.9 | -31% |
| 2024 | $18.9 | $20.7 | +9.4% |
| 2025 | $20.7 | $12.0 | -42% |
| 2026 YTD | $12.0 | $6.43 | -46% |
EMBC has finished lower in three of the last four years. It's down 46% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over EMBC on returns for 2026, with the stronger performance.